To achieve tumor-specific CD22 targeting, highly specific Neu5Ac analogue ligands were conjugated with NK–92MI cells through chemoenzymatic generation to enhance the therapeutic efficacy of the cell for better cancer treatment. The gene discussed is CD22; the disease is cancer.